Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Frequently asked questions
What sector does JBIO (JBIO) operate in?
JBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is JBIO (JBIO) current stock price?
As of the latest data, JBIO stock price is $14.74, with a previous close of $14.50. JBIO gained $0.24 in the last trading session, representing a 1.66% increase.
What is JBIO (JBIO) current market capitalization?
JBIO market cap is approximately 937.43 million.
What is JBIO (JBIO) Earnings Per Share (EPS)?
The trailing EPS is -$1.07, and the forward EPS is -$2.66.
What is JBIO (JBIO) EBITDA?
JBIO EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -58.91 million.
Does JBIO (JBIO) pay dividends?
No. JBIO does not pay a dividend.
What is JBIO (JBIO) beta (volatility) score?
JBIO has a beta of -0.165, indicating lower volatility than the overall market.